Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT03811561 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

A Research Study to Look at How Semaglutide Compared to Placebo Affects Diabetic Eye Disease in People With Type 2 Diabetes

Name: A Research Study to Look at How Semaglutide Compared to Placebo Affects Diabetic Eye Disease in People With Type 2 Diabetes — clinical trial record (NCT03811561)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

Study acronym: FOCUS

StatusActive, Not Recruiting

PhasePhase 3

SponsorNovo Nordisk A/S

Started2019-05-08

View on ClinicalTrials.gov ↗

This study will look at the long-term effects of semaglutide (active medicine) on diabetic eye disease when compared to placebo (dummy medicine). The study will be performed in people with type 2 diabetes. Participants will either get semaglutide or placebo in addition to their diabetes medicines - which treatment the participant gets is decided by chance. Participants will inject the study medicine using a pen-injector. The medicine must be injected in a skin fold in the stomach, thigh or upper arm once a week. The study will last for 5 years.

Amendment history 1 change detected by DataLookout

2026-05-01

Primary completion pushed: 2026-12-25 → 2027-11-07

Trial Details

NCT Number	NCT03811561
Lead Sponsor	Novo Nordisk A/S
Conditions	Diabetes Mellitus, Type 2
Enrollment	1,500 participants
Start Date	2019-05-08
Primary Completion	2027-11-07 (estimated)
Study Completion	2027-11-07 (estimated)
Updated on ClinicalTrials.gov	2026-09-09